We found that PRL-3 enhanced these cancer-associated phenotypes independently of its phosphatase activity, as effects were maintained in the phosphatase-dead C104D mutant but lost with the CNNM-binding deficient R138E variant. Here, PTP4A3 is linked to cancer.